(IBB)

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.

President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...

Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05...

Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides mor...

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...